![Amgen Biotech Experience (ABE) Program Office on X: "The @AmgenFoundation seeks to inspire the next generation of innovators. We're proud that its funding brings ABE to secondary students at 22 sites around Amgen Biotech Experience (ABE) Program Office on X: "The @AmgenFoundation seeks to inspire the next generation of innovators. We're proud that its funding brings ABE to secondary students at 22 sites around](https://pbs.twimg.com/media/Ey4xOuNW8AECtNh.png)
Amgen Biotech Experience (ABE) Program Office on X: "The @AmgenFoundation seeks to inspire the next generation of innovators. We're proud that its funding brings ABE to secondary students at 22 sites around
![Randomized phase-III study of low-dose cytarabine and etoposide + /− all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia | Scientific Reports Randomized phase-III study of low-dose cytarabine and etoposide + /− all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-023-41964-y/MediaObjects/41598_2023_41964_Fig1_HTML.png)
Randomized phase-III study of low-dose cytarabine and etoposide + /− all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia | Scientific Reports
![Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA - The Lancet Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA - The Lancet](https://www.thelancet.com/cms/asset/a768cb1b-3349-42a3-96ad-1caf4dc7a3e3/gr1.jpg)